Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open-Label, Rater Blinded Assessment of Optimal Treatment Change Strategy to Risperidone for Patients Intolerant of Olanzapine

NCT00378183 is registered in ClinicalTrials.gov with Janssen, LP as lead sponsor.

NCT NCT00378183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00378183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open-Label, Rater Blinded Assessment of Optimal Treatment Change Strategy to Risperidone for Patients Intolerant of Olanzapine
Lead sponsor
Janssen, LP
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2001
Completion date
May 31, 2002
Enrollment
120 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia